NASDAQ: COAG
Hemab Therapeutics Holdings Inc Earnings Dates, Reports, Calls

Hemab Therapeutics Holdings earnings were -$63.9M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest COAG earnings report on Dec 31, 2025 announced Q4 2025 earnings of N/A, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, COAG reported annual earnings of -$63.9M, with 31.2% growth.

COAG earnings history

Current Revenue
$0.0
Current Earnings
-$63.9M
Current Profit Margin
0%

COAG Return on Equity

Insufficient data to display

COAG Return on Assets

Current Company
-43.9%
Current Industry
-9.6%

Be the first to know when COAG announces earnings.

COAG Return on Capital Employed

Current Company
-34.84%
Current Industry
-3.7%

COAG vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ACHV-$53.60M-$54.65MN/A-$1.25
AAPG-$160.60M-$182.22MN/A-$2.05
AARD-$57.18M-$57.59MN/A-$2.93
ABUS-$33.04M-$33.50MN/A-$0.17
ABVX-$249.93M-$386.32MN/A-$5.55

Hemab Therapeutics Holdings Earnings Reports & History FAQ

What were Hemab Therapeutics Holdings's earnings last quarter?

Hemab Therapeutics Holdings (NASDAQ: COAG) reported Q4 2025 earnings per share (EPS) of N/A, up N/A year over year. Total COAG earnings for the quarter were N/A. In the same quarter last year, Hemab Therapeutics Holdings's earnings per share (EPS) was N/A.

If you're new to stock investing, here's how to buy Hemab Therapeutics Holdings stock.

Is Hemab Therapeutics Holdings profitable or losing money?

As of the last Hemab Therapeutics Holdings earnings report, Hemab Therapeutics Holdings is currently losing money. Hemab Therapeutics Holdings's net profit (also called net income) for the twelve months ending Dec 31, 2025 was -$63.91 million, a 31.22% increase year over year.

What was COAG's earnings growth in the past year?

As of Hemab Therapeutics Holdings's earnings date in Q2 2026, Hemab Therapeutics Holdings's earnings has grown year over year. COAG earnings in the past year totalled -$63.91 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.